**Consultation Response on Valuing Medicines - A Strategy for the Sustainable Use of Medicines in Northern Ireland**

December 2024 to February 2025

## OVERVIEW

Medicines have a vital role in helping to prevent, treat, and cure disease. They are our most common medical intervention and are relied upon to support health and wellbeing throughout life. However, medicines costs in Northern Ireland (NI) are increasing annually and have reached an all-time high of £875 million per year. We need to take action to protect access to medicines for the future.

Despite efforts to improve the efficient use of medicines in NI, our prescribing rates and costs per person remain consistently higher than in other countries within the United Kingdom. Without change, the Health and Social Care (HSC) service will struggle to continue funding expensive new medicines and technologies and keep up with the demand of an increasing and ageing population. Furthermore, the environmental impact of medications is significant, accounting for approximately 25% of carbon emissions within the National Health Service. Prescription medicines cannot be re-used by the HSC after supply to patients, levels of waste are too high, and there is a pressing need to reduce the carbon footprint of medicines and mitigate environmental risks.

This strategy sets out what we intend to do to help ensure the sustainable use of medicines and embed a culture of valuing medicines within our population and the HSC.

**The aim is to embed sustainable practice into all health and social care settings, promoting a culture that:**

* Allows equitable access to appropriate, safe and cost-effective medicines.
* Involves patients in decisions about their medicines, promotes preventive care, and offers options alongside prescribed medicines.
* Reduces waste and the environmental impact of medicines.
* Drives improvement through data, technology, research and innovation.

Businesses and citizens all benefit from the public services and amenities provided by the government. Contributing to these services helps ensure they remain available and continue to improve for the future.

The Department of Health (DoH) is therefore seeking views on ‘Valuing Medicines - A Strategy for the Sustainable use of Medicines in Northern Ireland’. Please note that it is advised that respondents should first read the consultation document before attempting to respond to these consultation questions.

## Why your views matter

Your voice matters, and your perspective is invaluable in designing a strategy for the sustainable use of medicines in NI. It is really important to have your say in how public services are shaped. The decisions made today will have far-reaching consequences for generations to come.

## Submission details

Please submit your responses by 26 February 2025 by completing the [Citizen Space online survey](https://consultations2.nidirect.gov.uk/doh-1/consultation-response-on-valuing-medicines-a-strat/). We would prefer responses using Citizen Space, however, if you wish to send an email or hard copy you should complete this consultation response document and submit your response using the correspondence details below:

Online: [Citizen Space online survey](https://consultations2.nidirect.gov.uk/doh-1/consultation-response-on-valuing-medicines-a-strat/)

Email: [VMSconsultation@health-ni.gov.uk](mailto:VMSconsultation@health-ni.gov.uk)

Mail: Valuing Medicines Consultation

Pharmaceutical Directorate

Room D4.10

Department of Health

Castle Buildings

Belfast

BT4 3SQ

If you have any questions or need assistance, please contact us using the above details.

## Privacy notice

We respect your privacy. Any personal information you provide will be handled in accordance with data protection laws. We will not publish your personal details.

Being transparent and providing accessible information to individuals about how we may use personal data is a key element of the Data Protection Act (DPA) and the EU General Data Protection Regulation (GDPR). The DoH is committed to building trust and confidence in our ability to process your personal information and protect your privacy.

For information on how we process your information, please see the privacy notice in **Annex A**.

**CONSULTEE DETAILS**

Q1. Are you responding as a:

Pharmacist ⬜

GP ⬜

Carer ⬜

Member of the public ⬜

Political representative ⬜

Service user ⬜

Social worker ⬜

Independent social care provider ⬜

Healthcare Professional/Staff ⬜

Voluntary & Community sector ⬜

Health & Social Care Trust ⬜

Local or district council ⬜

Trade Union ⬜

Regulatory authority ⬜

Professional body ⬜

Advocacy organisation ⬜

Academic body ⬜

Another NICS Department ⬜

Arm’s Length Body ⬜

Other public organisation ⬜

Part of an organisation/group ⬜

Other ⬜

**If you selected other, please specify:**

**Details:**

**QUESTIONS:**

**Views are invited on the following questions:**

This section relates to the **strategy goals** and seeks your views on the following targets:

**Target 1: Close the gap**

Outcome

* Reduce the historical gap between our current prescription (ingredient) cost per head and that in the rest of the UK in primary care.
* Manage equitable access to new medicines in secondary care and other high-cost treatment pathways cost-effectively.

**Target 2: Take climate action for better health**

Outcome

* Reduce medicines waste and embed lower carbon initiatives for medicines into HSC systems.

Q2. Do you believe that **‘Target 1: Close the gap’**, as outlined in the Strategy goals, is achievable?

Yes ⬜

No ⬜

Don’t know/No views ⬜

**If No, what do you see as the key barriers to achieving this target:**

**Comments:**

Q3. Do you believe that **‘Target 2: Take climate action for better health’**, as outlined in the Strategy goals, is achievable?

Yes ⬜

No ⬜

Don’t know/No views ⬜

**If No, what do you see as the key barriers to achieving this target:**

**Comments:**

**Theme 1: Ensure equitable access to appropriate, safe and cost-effective medicines**

This section relates to **Theme 1** and seeks your views on the following recommendations:

* 1. Through the Medicines Optimisation Regional Efficiency (MORE) programme continue to ensure that prescribing in all HSC sectors is in line with NI cost-effective medicines policies.
  2. Consult on actions to restrict or stop prescribing of low priority medicines including those with poor evidence of effectiveness and medicines available over the counter for minor conditions.
  3. Improve the cost effectiveness of supply models for non-medicinal products, including nutritional products, enteral feeds, specialist dressings, and irrigation products and appliances such as stoma care and incontinence management.
  4. Introduce a regional system through the NI Drug Tariff to enable equitable access to ‘specials’ cost-effectively.
  5. Strengthen the regional arrangements for commissioning of medicines and related medical technologies.
  6. Introduce a scheme for utilising a portion of medicines efficiency savings for improvement initiatives related to sustainable medicines practice.

Q4. To what extent do you agree with the recommendations listed under **Theme 1: Ensure equitable access to appropriate, safe and cost-effective medicines**?

Strongly Agree ⬜

Agree ⬜

Neutral ⬜

Disagree ⬜

Strongly Disagree ⬜

**Please provide any comments or suggestions regarding Theme 1:**

Q5. Do you believe the recommendations listed under **Theme** 1 will be effective in ensuring equitable access to appropriate, safe and cost-effective medicines?

Yes ⬜

No ⬜

**Please share any additional suggestions to improve the recommendations in the text box below:**

**Comments:**

**Theme 2: Involve patients in decisions about their medicines, promote preventive care, and offer options alongside prescribed medicines**

This section relates to **Theme 2** and seeks your views on the following recommendations:

* 1. Embed shared decision making between clinicians and patients into practice in primary and secondary care when starting, changing and stopping medication.
  2. Promote health literacy initiatives to encourage communities and individuals to develop the knowledge they need to be more involved in decisions about their medicines.
  3. Raise awareness across the HSC of preventive health initiatives available for patients and the public.
  4. Improve access to non-medical therapies alongside medical treatments through the continued roll out of multi-disciplinary teams in primary care and the introduction of a regional approach to social prescribing.
  5. Promote and expand the Pharmacy First service so that more conditions can be treated cost-effectively in community pharmacies, including more advanced treatments provided by independent prescribers.

Q6. To what extent do you agree with the recommendations listed under **Theme 2: Involve patients in decisions about their medicines, promote preventive care, and offer options alongside prescribed medicines**?

Strongly Agree ⬜

Agree ⬜

Neutral ⬜

Disagree ⬜

Strongly Disagree ⬜

**Please provide any comments or suggestions regarding Theme 2:**

Q7. Do you believe the recommendations listed under **Theme** 2 will be effective in involving patients in decisions about their medicines, promoting preventive care and offering alternative to medicines?

Yes ⬜

No ⬜

**Please share any additional suggestions to improve the recommendations in the text box below:**

**Comments:**

**Theme 3: Reduce waste and the environmental impact of medicines**

This section relates to **Theme 3** and seeks your views on the following recommendations:

* 1. Identify a lead for green medicines optimisation within the MORE Programme to develop and oversee a new regional improvement programme to reduce the carbon footprint associated with medicines in the HSC.
  2. Include a focus on over-prescribing in the MORE Programme to target initiatives to reduce waste and ensure that all patients on regular medications have their medicines reviewed at least annually.
  3. Raise awareness of the harm caused by medicines waste, actions that can be taken to stop it, and the use of Medicine Waste Schemes in community pharmacies to reduce the amount of harmful waste entering waterways and landfill.

Q8. To what extent do you agree with the recommendations listed under **Theme 3: Reduce waste and the environmental impact of medicines**?

Strongly Agree ⬜

Agree ⬜

Neutral ⬜

Disagree ⬜

Strongly Disagree ⬜

**Please provide any comments or suggestions regarding Theme 3:**

Q9. Do you believe the recommendations listed under **Theme 3** will be effective in reducing waste and the environmental impact of medicines?

Yes ⬜

No ⬜

**Please share any additional suggestions to improve the recommendations in the text box below:**

**Please share any additional suggestions to improve the recommendations in the text box below:**

**Comments:**

**Theme 4: Drive improvement through data, technology, research and innovation**

This section relates to **Theme 4** and seeks your views on the following recommendations:

* 1. Prioritise the implementation of the ePharmacy Programme in primary care settings, including electronic transmission of prescriptions and a digital system for pharmacy services, to streamline supply processes, enhance efficiency and reduce administrative burdens.
  2. Utilise clinical decision support systems in primary and secondary care to help prescribers choose cost-effective and lower carbon options and notify of medicines shortages.
  3. Establish a Northern Ireland repository of data relating to medicines, drawing from primary and secondary care sources to map and track information up to population level.
  4. Introduce enhanced software systems to monitor and track primary care prescribing data to make it quicker to access, easier to understand, interrogate and share at different system levels.
  5. Through the roll out of Encompass in secondary care and the General Practitioner Intelligence Platform (GPIP) in primary care, harness opportunities for optimizing the cost-effective and environmentally safer prescribing, supply, and administration of medicines.
  6. Through the Medicines Optimisation Innovation Centre develop a programme of research and innovation in the sustainable use of medicines.

Q10. To what extent do you agree with the recommendations listed under **Theme 4: Drive improvement through data, technology, research and innovation**?

Strongly Agree ⬜

Agree ⬜

Neutral ⬜

Disagree ⬜

Strongly Disagree ⬜

**Please provide any comments or suggestions regarding Theme 4:**

Q11. Do you believe the recommendations listed under **Theme 4** will be effective in driving improvement through data, technology, research and innovation?

Yes ⬜

No ⬜

**Please share any additional suggestions to improve the recommendations in the text box below:**

**Comments:**

**Valuing Medicines Strategy: Have we missed anything?**

Q12. Taking into account **all the proposals set out in the Valuing Medicines Strategy**; do you think there are any areas we may have missed?

Yes ⬜

No ⬜

Not sure ⬜

**If your answer is Yes, please provide further detail and explanation below:**

**Equality and Human Rights**

Q13. Do you consider that any of the proposed recommendations might have an adverse impact on any of the following equality groups? Please select all that apply and provide any comments below on how these adverse impacts could be reduced or improved.

|  |  |  |  |
| --- | --- | --- | --- |
| Age | | ⬜ | |
| Men and Women generally | | ⬜ | |
| Racial Group | | ⬜ | |
| Sexual Orientation | | ⬜ | |
| Marital Status | | ⬜ | |
| Disability | | ⬜ | |
| Religious Belief | | ⬜ | |
| Political Opinion | | ⬜ | |
| Dependents | | ⬜ | |
|  | |  | |
|  | |  | |

|  |
| --- |
| **Comments:** |

Q14. Are you aware of any indication or evidence – qualitative or quantitative – that the recommendations set out in the consultation document may have an adverse impact on equality of opportunity or on good relations?

Yes ⬜ No ⬜

**If Yes, please give details as to what could be added or removed to alleviate the adverse impact:**

**Details:**

Q15. Is there an opportunity to better promote equality of opportunity or good relations

among any of the nine equality groups identified under Section 75 of the NI Act 1998?

Yes ⬜ No ⬜

Q16. If you answered yes to Q15, please tick and identify all relevant groups and comment below on how the Department could better promote equality of opportunity or good relations among these groups.

|  |  |  |  |
| --- | --- | --- | --- |
| Age | | ⬜ | |
| Men and Women generally | | ⬜ | |
| Racial Group | | ⬜ | |
| Sexual Orientation | | ⬜ | |
| Marital Status | | ⬜ | |
| Disability | | ⬜ | |
| Religious Belief | | ⬜ | |
| Political Opinion | | ⬜ | |
| Dependents | | ⬜ | |
|  | |  | |

|  |
| --- |
| **Comments:** |

Q17. Are there any aspects of the proposals and recommendations where potential human rights violations may occur?

Yes ⬜No ⬜

If yes, please give details

|  |
| --- |
| **Comments:** |

**Rural Impact**

Q18. Are the recommendations or proposals set out in this consultation document likely to have an adverse impact on rural areas?

Yes ⬜ No ⬜

**If Yes, please give details as to what could be added or removed to alleviate the adverse impact?**

**Details:**

**Thank you for your comments.**

**Annex A - Privacy Notice – Consultations (Department of Health)**

Data Controller Name: Department of Health (DoH)

Address: Castle Buildings, Stormont, BELFAST, BT4 3SG

Email: [VMSconsultation@health-ni.gov.uk](mailto:VMSconsultation@health-ni.gov.uk)

Telephone: 02890523146

Data Protection Officer Name: Charlene Maher

Email: [DPO@health-ni.gov.uk](mailto:brendan.g.oneill@health-ni-gov.uk)

Being transparent and providing accessible information to individuals about how we may use personal data is a key element of the [Data Protection Act (DPA)](http://www.legislation.gov.uk/ukpga/2018/12/contents/enacted) and the [UK General Data Protection Regulation (UK GDPR)](https://ico.org.uk/for-organisations/guide-to-data-protection/guide-to-the-general-data-protection-regulation-gdpr/). The Department of Health (DoH) is committed to building trust and confidence in our ability to process your personal information and protect your privacy.

**Purpose for processing**

While we are not seeking to process personal data as part of this consultation and would encourage you to be mindful of the information you disclose as part of your responses, if you disclose any personal data we will ensure we process this according to the requirements of Data Protection law. We will process any data provided in response to consultations for the purpose of informing the development of our policy, guidance, or other regulatory work in the subject area of the request for views. We will publish a summary of the consultation responses and, in some cases, the responses themselves but these will not contain any personal data. We will not publish the names or contact details of respondents but will include the names of organisations responding.

If you have indicated that you would be interested in contributing to further Departmental work on the subject matter covered by the consultation, then we might process your contact details to get in touch with you.

**Lawful basis for processing**

The lawful basis we are relying on to process your personal data is Article 6(1)(e) of the UK GDPR, which allows us to process personal data when this is necessary for the performance of our public tasks in our capacity as a Government Department.

We will only process any special category personal data you provide, which reveals racial or ethnic origin, political opinions, religious belief, health or sexual life/orientation when it is necessary for reasons of substantial public interest under Article 9(2)(g) of the UK GDPR, in the exercise of the function of the department, and to monitor equality.

**How will your information be used and shared**

We process the information internally for the above stated purpose. We don't intend to share your personal data with any third party. Any specific requests from a third party for us to share your personal data with them will be dealt with in accordance with the provisions of the data protection laws.

**How long will we keep your information**

We will retain consultation response information until our work on the subject matter of the consultation is complete, and in line with the Department’s approved Retention and Disposal Schedule [Good Management, Good Records](https://www.health-ni.gov.uk/topics/good-management-good-records) (GMGR).

**What are your rights?**

* You have the right to obtain confirmation that your data is being [processed, and access to your personal data](https://ico.org.uk/for-organisations/guide-to-the-general-data-protection-regulation-gdpr/individual-rights/right-of-access/)
* You are entitled to have personal data [rectified if it is inaccurate or incomplete](https://ico.org.uk/for-organisations/guide-to-the-general-data-protection-regulation-gdpr/individual-rights/right-to-rectification/)
* You have a right to have personal data [erased and to prevent processing](https://ico.org.uk/for-organisations/guide-to-the-general-data-protection-regulation-gdpr/individual-rights/right-to-erasure/), in specific circumstances
* You have the right [to ‘block’ or suppress processing](https://ico.org.uk/for-organisations/guide-to-the-general-data-protection-regulation-gdpr/individual-rights/right-to-restrict-processing/) of personal data, in specific circumstances
* You have the right to [data portability](https://ico.org.uk/for-organisations/guide-to-the-general-data-protection-regulation-gdpr/individual-rights/right-to-data-portability/), in specific circumstances
* You have the right to [object to the processing](https://ico.org.uk/for-organisations/guide-to-the-general-data-protection-regulation-gdpr/individual-rights/right-to-object/), in specific circumstances
* You have rights in relation to [automated decision making and profiling](https://ico.org.uk/for-organisations/guide-to-the-general-data-protection-regulation-gdpr/individual-rights/rights-related-to-automated-decision-making-including-profiling/).

How to complain if you are not happy with how we process your personal information

If you wish to request access, object or raise a complaint about how we have handled your data, you can contact our Data Protection Officer using the details above.

If you are not satisfied with our response or believe we are not processing your personal data in accordance with the law, you can complain to the Information Commissioner at:

Information Commissioner’s Office

Wycliffe House

Water Lane

Wilmslow

Cheshire SK9 5AF

[ICO Complaints Form](https://ico.org.uk/make-a-complaint/data-protection-complaints/data-protection-complaints/)